Reliability of Paired Associative Stimulation-induced Neuroplasticity After Stroke
NCT ID: NCT03861806
Last Updated: 2022-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
15 participants
INTERVENTIONAL
2019-04-17
2022-09-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Spinal Plasticity to Enhance Motor Retraining After Stroke
NCT03645122
Novel Non-invasive Brain Stimulation Techniques in Neurological Rehabilitation
NCT05766059
Paired Associative Stimulation in Post-stroke Hand Motor Deficits
NCT02284087
Finding an Optimal Latency for Paired Associative Stimulation in People With Chronic Stroke
NCT02188420
Combining PAS to Non-invasive VNS
NCT04938284
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There is large interindividual variability in individuals' responses to PAS, which may be useful in examining its relationship to motor learning, but the reliability of the measure will need to be assessed prior to using this measure to make inferences about a subject's general capacity to learn motor tasks. The reliability of the response to PAS and its relationship to clinical factors such as stroke severity, has not been well studied in patients with stroke. Results from a preliminary experiment suggest that stroke patients who have a robust response to facilitatory PAS on their unaffected hemisphere have more severe motor deficits than those who do not have a significant response to PAS.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PAS true
Participants will receive paired associative stimulation therapy with a modulatory inter-stimulus interval.
PAS true
Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
PAS sham
Participants will receive paired associative stimulation therapy with a non modulatory inter-stimulus interval.
PAS sham
Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to not modulate corticospinal excitability.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PAS true
Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
PAS sham
Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to not modulate corticospinal excitability.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to give informed consent and understand the tasks involved.
* Age over 18 years.
Exclusion Criteria
* Contraindications to TMS: history of seizure/epilepsy, pacemaker, other neurological disorders, brain surgery, metal implant/fragment in the head, pregnancy
* Taking medications or substances that are known to affect PAS-induced plasticity within the past 2 months: selective serotonin reuptake inhibitors, dopamine, dopamine agonists, haloperidol, lithium, acetylcholinesterase inhibitors, beta-blockers, nimodipine, levetiracetam, ethosuximide, benzodiazepines, baclofen, nicotine
* Peripheral neuropathy or history of nerve injury in the paretic upper limb.
* Social and/or personal circumstances that interfere with ability to return for all study visits.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Burke Medical Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tomoko Kitago
Lab Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Burke Neurological Institute
White Plains, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HMRL-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.